Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive with news the company, which has filed over a dozen patents, has been granted their second in relation to its proprietary cannabidiol formulations around the hard pill format.
Goldstein telling Proactive what this means for the company and he also said the company plans to prove greater bio-availability through a blood level study at a third party Clinical Research Organization that is currently in the planning stages.